TocilizumabV1, Main, Merge, indexHead, Idat.i

Index : Idat.i

Les termes de plus forte occurence

4	0379-0355:2010:Tomillero A:gateways:to:clinical
3	0379-0355:2008:Tomillero A:gateways:to:clinical
2	1615-9306:2008:Taga A:analysis:of:an
2	1567-5769:2008:Uchiyama Y:anti:il:receptor
2	1567-5769:2005:Mihara M:tocilizumab:inhibits:signal
2	1462-0324:2010:Shima Y:the:skin:of
2	1462-0324:2008:Hashizume M:il:trans:signalling
2	1368-5031:2011:Alves J:tocilizumab:is:there
2	1080-0549:2005:Yokota S:clinical:study:of
2	1080-0549:2005:Smolen J:pro:inflammatory:cytokines
2	1080-0549:2005:Nishimoto N:clinical:studies:in
2	1078-0432:2011:Tawara I:interleukin:modulates:graft
2	1053-8569:2013:Curtis J:identifying:newly:approved
2	0946-1965:2013:Zhang X:pharmacokinetics:and:pharmacodynamics
2	0946-1965:2013:Xiaoping Zhang:pharmacokinetics:and:pharmacodynamics
2	0946-1965:2013:Morcos P:pharmacokinetics:and:pharmacodynamics
2	0925-5710:2007:Kanda J:reversible:cardiomyopathy:associated
2	0379-0355::Bayes M:gateways:to:clinical
2	0379-0355:2009:Tomillero A:gateways:to:clinical
2	0379-0355:2007:Bayes M:gateways:to:clinical
2	0379-0355:2005:Bayes M:gateways:to:clinical
2	0340-1855:2011:Kruger K:kombinationsbehandlung:von:methotrexat
2	0340-1855:2010:Wollenhaupt J:nicht:tnf:biologika
2	0340-1855:2010:Gause A:empfehlungen:der:deutschen
2	0315-162X:2014:Yokota S:longterm:safety:and
2	0315-162X:2014:Koike T:effectiveness:and:safety
2	0315-162X:2014:Keystone E:continued:benefit:of
2	0315-162X:2014:Elkayam O:tocilizumab:in:adult
2	0315-162X:2014:Aoki C:discrepancy:between:clinical
2	0315-162X:2013:Tombetti E:treatment:of:refractory
2	0315-162X:2013:Shimamoto K:serum:interleukin:before
2	0315-162X:2013:Ikeda K:correlation:of:radiographic
2	0315-162X:2013:Genovese M:longterm:safety:and
2	0315-162X:2013:Fleischmann R:tocilizumab:inhibits:structural
2	0315-162X:2013:Aguilar Lozano L:sustained:clinical:remission
2	0315-162X:2012:Richez C:tocilizumab:treatment:decreases
2	0315-162X:2012:Mesko B:peripheral:blood:gene
2	0315-162X:2012:Fragiadaki K:sleep:disturbances:and
2	0315-162X:2011:Singh J:tocilizumab:for:rheumatoid
2	0315-162X:2011:Roux C:ophthalmic:herpes:zoster
2	0315-162X:2011:Launois R:comparison:of:certolizumab
2	0315-162X:2011:Kume K:tocilizumab:monotherapy:reduces
2	0315-162X:2009:Kawashiri S:proinflammatory:cytokines:synergistically
2	0303-464X::Fonseca J:portuguese:guidelines:for
2	0301-1526:2012:Schumacher A:castleman:s:disease
2	0277-0008:2011:Devine E:effectiveness:of:biologic
2	0269-4727:2013:Carnovale C:a:case:of
2	0171-2004:2008:Nishimoto N:humanized:antihuman:il
2	0040-5957:2011:Fabre S:approches:pharmacologiques:en
2	0032-5473:2010:Suresh E:recent:advances:in
2	0022-3417:2011:Shinriki S:interleukin:signalling:regulates
2	0022-3085:2009:Kudo M:antitumor:effect:of
2	0021-9746:2010:Sato Y:multicentric:castleman:s
2	0012-6667:2009:Oldfield V:tocilizumab:a:review
2	0008-5472:2007:Yoshio Hoshino N:establishment:of:a
2	0007-0963:2014:Jayasekera P:a:case:of
2	0007-0963:2010:Laurent S:onset:of:psoriasis
2	0004-3591:2010:Illei G:tocilizumab:in:systemic
2	0004-3591:2010:Garnero P:rapid:and:sustained
2	0004-3591:2008:Nishimoto N:successful:treatment:of
2	0004-3591:2008:Genovese M:interleukin:receptor:inhibition
2	0004-3591:2006:Okuda Y:successful:use:of
2	0004-3591:2006:Maini R:double:blind:randomized
2	0003-4967:2013:Specker C:ab:tocilizumab:in
2	0003-4967:2013:Shirota Y:impact:of:anti
2	0003-4967:2013:Kume K:ab:tocilizumab:improves
2	0003-4967:2013:Kanayama Y:ab:radiographic:progression
2	0003-4967:2013:Foeldvari I:ab:looking:for
2	0003-4967:2013:Dougados M:adding:tocilizumab:or
2	0003-4967:2012:Yazici Y:efficacy:of:tocilizumab
2	0003-4967:2012:Smolen J:tocilizumab:inhibits:progression
2	0003-4967:2012:Schoels M:comparative:effectiveness:and
2	0003-4967:2012:Sakai R:drug:retention:rates
2	0003-4967:2012:Mori S:impact:of:tocilizumab
2	0003-4967:2012:Cohen C:efficacy:of:tocilizumab
2	0003-4967:2012:Bykerk V:tocilizumab:in:patients
2	0003-4967:2011:Salliot C:indirect:comparisons:of
2	0003-4967:2011:Ogata A:improvement:of:hba
2	0003-4967:2011:Muhammad K:impact:of:il
2	0003-4967:2011:Leffers H:efficacy:of:abatacept
2	0003-4967:2011:Koike T:postmarketing:surveillance:of
2	0003-4967:2011:Inaba Y:radiographic:improvement:of
2	0003-4967:2011:Iking Konert C:performance:of:the
2	0003-4967:2011:Burmester G:effectiveness:and:safety
2	0003-4967:2010:Nam J:current:evidence:for
2	0003-4967:2010:Jones G:comparison:of:tocilizumab
2	0003-4967:2010:Henes J:mixed:response:to
2	0003-4967:2009:Nishimoto N:long:term:safety
2	0003-4967:2009:Hirao M:laboratory:and:febrile
2	0003-4967:2009:De Bandt M:tocilizumab:for:multirefractory
2	0003-4967:2008:Emery P:il:receptor:inhibition
2	0003-4967:2007:Sacre S:could:toll:like
2	0003-4967:2007:Nishimoto N:study:of:active
1	8756-7938:2015:Dwivedi P:role:of:gold
1	8756-7938:2012:Marichal Allardo P:state:of:the
1	2629-3269:2020:Ulrich H:cd:as:a
1	2586-6583:2020:Koerner J:correlation:of:early
1	2542-4513:2019:Frikha F:tocilizumab:for:refractory
1	2531-1379:2019:Suega K:predicting:hepcidin:level
1	2531-0429:2020:Tonelli R:never:give:up
1	2509-4262:2019:Boytsov N:impact:of:plan
1	2473-9529:2020:Zhang X:first:case:of
1	2473-9529:2020:Tan A:chimeric:antigen:receptor
1	2473-9529:2020:Schuster S:grading:and:management
1	2473-9529:2020:Pennisi M:comparing:car:t
1	2473-9529:2020:Nardi V:clinical:response:to
1	2473-9529:2020:Maziarz R:grading:of:neurological
1	2473-9529:2020:Awasthi R:tisagenlecleucel:cellular:kinetics
1	2473-9529:2019:Sidana S:car:t:cell
1	2473-9529:2019:Shah N:clonal:expansion:of
1	2473-9529:2019:Popescu N:monocyte:procoagulant:responses
1	2473-9529:2019:Cooley S:first:in:human
1	2473-9529:2019:Bishop M:tisagenlecleucel:in:relapsed
1	2473-9529:2017:Vick E:proliferation:through:activation
1	2451-9936:2017:Russell D:tocilizumab:as:a
1	2405-4704:2020:Blanco J:covid:in:patients
1	2397-1983:2017:Khanna D:standardization:of:the
1	2397-1983:2016:Johnson S:systemic:sclerosis:trial
1	2379-3708:2016:Wunderlich M:a:xenograft:model
1	2373-8731:2017:Shin B:tocilizumab:anti:il
1	2373-8731:2015:Liu H:myroides:infection:in
1	2352-4928:2018:Janakiraman K:novel:nano:therapeutic
1	2352-4820:2019:Nameirakpam J:genetics:on:early
1	2352-3409:2016:Lin J:datasets:of:yy
1	2347-5625:2019:Barber F:adverse:events:of
1	2332-7812:2019:Rempe T:a:case:of
1	2328-9503:2018:Shin Y:bortezomib:treatment:for
1	2328-8957:2018:Jarosinski K:cellular:stress:response
1	2326-5191:2019:Ter Haar N:treatment:to:target
1	2326-5191:2019:Taylor P:cardiovascular:safety:during
1	2326-5191:2019:Stone J:glucocorticoid:dosages:and
1	2326-5191:2019:Charles Choeman C:risk:factors:for
1	2326-5191:2018:Stifano G:skin:gene:expression
1	2326-5191:2018:Kjelgaard Etersen C:translational:biomarkers:and
1	2326-5191:2018:Cheng L:brief:report:a
1	2326-5191:2018:Brunner H:subcutaneous:abatacept:in
1	2326-5191:2018:Berti A:circulating:cytokine:profiles
1	2326-5191:2017:Weinblatt M:a:phase:iii
1	2326-5191:2017:Vanhoutte F:efficacy:safety:pharmacokinetics
1	2326-5191:2015:Lovell D:long:term:safety
1	2326-5191:2014:Ilowite N:the:randomized:placebo
1	2314-8861:2020:Chen Y:genetic:association:and
1	2314-8861:2019:Zhou J:the:clinical:features
1	2314-8861:2019:Yan D:the:clinical:features
1	2314-8861:2019:Xu H:vascular:macrophages:in
1	2314-8861:2019:Guan Q:a:comprehensive:review
1	2314-8861:2019:Costanza M:type:inflammatory:responses
1	2314-8861:2019:Chen Y:immunotherapy:deriving:from
1	2314-8861:2017:Sethi S:desensitization:overcoming:the
1	2314-8861:2017:Ravindranath M:the:humoral:theory
1	2314-8861:2016:Sawaf M:follicular:helper:t
1	2314-6133:2020:Wollin L:effects:of:nintedanib
1	2314-6133:2020:Wang X:the:biomarkers:for
1	2314-6133:2020:Wang H:current:progress:on
1	2314-6133:2019:Samotij D:biologics:in:the
1	2314-6133:2019:Lacheta D:immunological:aspects:of
1	2314-6133:2019:Feng X:body:mass:index
1	2314-6133:2015:Rossi J:targeted:therapies:in
1	2314-6133:2013:Truchetet M:il:in:the
1	2307-8960:2015:Ponte C:giant:cell:arteritis
1	2296-9705::Yabuuchi J:aa:amyloidosis:and
1	2296-9381:2016:Nienhuis H:the:prevalence:and
1	2296-4681:2016:Parkash V:bilateral:ocular:myositis
1	2287-979X:2019:Ali N:chimeric:antigen:t
1	2287-979X:2017:Mahajan G:hepcidin:and:iron
1	2287-2728:2019:Fousekis F:extrahepatic:manifestations:of
1	2251-8363:2015:Esmaili H:an:update:on
1	2251-6085:2019:Su G:the:effect:of
1	2250-1541:2016:Hirsch J:tocilizumab:efficacy:in
1	2249-4863:2020:Batta A:trends:in:fda
1	2234-3806:2019:Benucci M:laboratory:monitoring:of
1	2233-7385:2020:Yoon S:chimeric:antigen:receptor
1	2229-5178:2019:Sangolli P:vasculitis:a:checklist
1	2229-5097:2019:Canavero S:advancing:the:technology
1	2229-5097:2018:Zarei S:comprehensive:review:of
1	2228-5652:2019:Sanie Jahromi F:propagation:of:limbal
1	2222-3959:2019:Wu X:tocilizumab:promotes:corneal
1	2214-3599:????:Behin A:new:pathways:and
1	2214-3300:2017:Hou T:tafro:syndrome:a
1	2213-7165:2020:Dastan F:continues:renal:replacement
1	2213-2600:2020:Kirby T:south:america:prepares
1	2213-2198:2020:Lipworth B:weathering:the:cytokine
1	2213-1779:2020:Mehra M:covid:illness:and
1	2213-0071:2018:Katsumata Y:tocilizumab:effective:multicentric
1	2212-6287:2014:Watanabe N:hip:arthroscopic:synovectomy
1	2211-3835:2019:Lv C:xenobiotic:receptors:in
1	2211-3835:2019:Li Y:current:trends:in
1	2211-0348:2020:Vishnevetsky A:rethinking:high:risk
1	2211-0348:2020:Novi G:covid:in:a
1	2211-0348:2020:Giovannoni G:anti:cd:immunosuppressive
1	2211-0348:2020:Carnero Contentti E:immunosuppression:during:the
1	2199-1154:2016:Gu T:comparing:biologic:cost
1	2199-1154:2015:Johnston S:comparison:of:healthcare
1	2199-1154:2015:Beck M:analysis:and:breakdown
1	2198-6576:2020:Tarrant J:filgotinib:a:jak
1	2198-6576:2020:Pappas D:methotrexate:discontinuation:and
1	2198-6576:2020:Best J:real:world:persistence
1	2198-6576:2020:Best J:comparative:cost:per
1	2198-6576:2019:Wells A:immunogenicity:of:sarilumab
1	2198-6576:2019:Reed G:real:world:comparative
1	2198-6576:2019:Radawski C:patient:perceptions:of
1	2198-6576:2019:Pappas D:patterns:of:prednisone
1	2198-6576:2019:Haraoui B:tocilizumab:patterns:of
1	2198-6576:2019:Gale S:characterizing:disease:manifestations
1	2198-6576:2019:Gale S:adverse:events:in
1	2198-6576:2019:Emery P:risk:of:malignancies
1	2198-6576:2019:Demizio D:autoimmunity:and:inflammation
1	2198-6576:2019:Darloy J:tocilizumab:effectiveness:after
1	2198-6576:2019:Best J:risk:of:potential
1	2198-6576:2019:Belasco J:psoriatic:arthritis:what
1	2198-6576:2018:Rubbert Roth A:a:review:of
1	2198-6576:2018:Harrold L:real:world:comparative
1	2198-6576:2018:Haraoui B:real:world:tocilizumab
1	2198-6576:2018:Gale S:risk:associated:with
1	2198-6576:2018:De Vlam K:skin:involvement:in
1	2198-6576:2017:Wilton K:malignancy:incidence:management
1	2198-6576:2017:Verhoef L:bdmard:dose:reduction
1	2198-6576:2017:Kivitz A:usability:and:patient
1	2198-6576:2017:Harrold L:impact:of:tocilizumab
1	2198-6576:2016:Soubrier M:concomitant:use:of
1	2198-6576:2016:Pappas D:dosing:of:intravenous
1	2198-6576:2016:Monemi S:incidence:of:gastrointestinal
1	2198-6576:2016:Kivitz A:long:term:safety
1	2198-6576:2015:Negoescu A:refining:the:management
1	2198-6576:2015:Johnston S:comparison:of:biologic
1	2198-6002:2018:Stingl C:an:update:on
1	2198-6002:2017:Sood A:an:update:on
1	2198-6002:2016:Young A:hand:impairment:in
1	2198-6002:2016:Kafaja S:management:of:widespread
1	2195-5840:2012:Reiff A:treatment:of:systemic
1	2193-8245:2019:Hodgson N:current:understanding:of
1	2193-8245:2019:Al Mousawi A:reviewing:the:pathophysiology
1	2192-4449:2018:Noda Narita S:tafro:syndrome:with
1	2192-4449:2017:Fujiki T:successful:treatment:by
1	2192-4449:2014:Yamada S:tocilizumab:induced:remission
1	2192-4449:2012:Maeshima A:efficacy:of:tocilizumab
1	2190-5991:2019:Pettersen K:autocrine:activin:a
1	2190-5991:2017:Tournadre A:changes:in:body
1	2190-5991:2012:Ebner N:recent:developments:in
1	2186-3644:2014:Tombetti E:anti:cytokine:treatment
1	2168-8184:2019:Huang I:early:initiation:of
1	2168-8184:2016:Ahmed M:refractory:case:of
1	2168-6149:2018:Finke C:association:of:visual
1	2168-6106:2017:Wadstrom H:malignant:neoplasms:in
1	2168-6068:2020:Schneeweiss M:risk:of:inflammatory
1	2167-8707:2016:Mendoza F:treatment:of:rapidly
1	2165-591X:2015:Lam L:anti:inflammatory:therapies
1	2165-591X:2013:Fiala M:tocilizumab:infusion:therapy
1	2165-591X:2012:Mizwicki M:tocilizumab:attenuates:inflammation
1	2164-5515:2018:Oishi S:treatment:of:active
1	2164-5515:2018:Katsiari C:immunotherapy:of:systemic
1	2164-5515:2018:Bahuaud M:immunogenicity:and:persistence
1	2163-8306:2014:Kretsos K:model:based:optimal
1	2163-8306:2014:Dwivedi G:a:multiscale:model
1	2163-0402:2016:Jewell P:tocilizumab:associated:multifocal
1	2162-4011:2020:Vanmeerbeek I:trial:watch:chemotherapy
1	2162-4011:2019:Sakamoto S:intraperitoneal:cancer:immune
1	2162-4011:2018:Garcia Martinez E:trial:watch:immunostimulation
1	2162-4011:2018:Franconieri F:superior:efficacy:and
1	2162-4011:2017:Galluzzi L:cars:on:a
1	2162-4011:2017:Berti A:tocilizumab:in:patients
1	2162-4011:2016:Mohr A:regulatory:b:lymphocyte
1	2162-4011:2016:Ferrero E:plasma:chromogranin:a
1	2162-4011:2015:Vacchelli E:trial:watch:immunostimulation
1	2162-4011:2015:Aranda F:trial:watch:adoptive
1	2162-3619:2015:Tedesco S:successful:treatment:of
1	2160-763X:2019:Chow V:pharmacokinetic:similarity:of
1	2160-763X:2014:Kretsos K:safety:and:pharmacokinetics
1	2155-9899:2016:Malemud C:matrix:metalloproteinase:production
1	2151-464X:2020:Morgan C:how:do:glucocorticoids
1	2151-464X:2015:Dougados M:evaluation:of:the
1	2151-464X:2013:Ringold S:update:of:the
1	2151-464X:2012:Unizony S:tocilizumab:for:the
1	2151-464X:2012:Singh J:update:of:the
1	2151-464X:2012:Simsek I:incomplete:reporting:of
1	2150-5349:2015:Hosseini Carroll P:pregnancy:and:inflammatory
1	2150-0878::Freyer C:tisagenlecleucel:the:first
1	2149-2263:2019:Segiet O:role:of:interleukins
1	2148-5046:2019:Huang H:body:mass:index
1	2148-5046:2019:Ata N:certolizumab:pegol:treatment
1	2148-4902:2019:Cakan M:the:necessity:efficacy
1	2147-9720:2020:Glaser D:linear:scleroderma:of
1	2147-9720:2020:Aeschlimann F:childhood:onset:takayasu
1	2147-9720:2019:Y Ld Z M:pediatric:behcet:s
1	2147-9720:2019:Reiff D:characteristics:of:coexisting
1	2147-9720:2019:Mothojakan N:does:biologic:survival
1	2147-9720:2019:Krutzke S:baricitinib:in:therapy
1	2147-9720:2019:Crayne C:pediatric:macrophage:activation
1	2147-9720:2019:Cerda O:tuberculin:test:conversion
1	2147-9720:2019:Carri N Barbera I:successful:treatment:of
1	2147-9720:2018:Y Lmaz S:recurrence:of:proteinuria
1	2147-9720:2016:Karada O:viral:hepatitis:screening
1	2147-9720:2015:Unlu O:the:clinical:significance
1	2147-9720:2015:Alibaz Ner F:recent:advances:in
1	2147-9720:2015:Akasbi N:successful:treatment:of
1	2146-4596:2018:Upadia J:a:familial:case
1	2095-9907:2019:Li D:genetically:engineered:t
1	2095-9907:2016:Bogdanovich S:human:igg:antibodies
1	2095-882X:2020:Xie L:interpretation:of:the
1	2095-8811:2016:Choudhary M:interleukin:role:in
1	2095-4700:2019:Zhu W:ankylosing:spondylitis:etiology
1	2095-4700:2019:Li J:iguratimod:a:valuable
1	2095-0217:2020:Zhou M:coronavirus:disease:covid
1	2093-6966:2019:Kesharwani D:rheumatiod:arthritis:an
1	2092-7355:2019:Han J:the:first:case
1	2090-8040:2014:Yang H:involvement:of:nf
1	2090-8040:2012:Rossi Semerano L:is:still:s
1	2090-8040:2012:Mavragani C:adult:onset:still
1	2090-8040:2012:Giampietro C:anti:interleukin:agents
1	2090-8040:2012:Efthimiou P:adult:onset:still
1	2090-8040:2011:Gurion R:systemic:arthritis:in
1	2090-6889:2020:Ishii Y:successful:treatment:of
1	2090-6889:2019:Thapa B:a:case:of
1	2090-6889:2019:Quartuccio L:seronegative:arthritis:and
1	2090-6889:2019:Fujita Y:fifty:two:week
1	2090-6889:2019:De Guerra V:a:case:report
1	2090-6889:2019:Alahmari H:rituximab:induced:psoriasis
1	2090-6889:2018:Ikeuchi H:hepatitis:e:during
1	2090-6889:2018:Filippini M:a:case:of
1	2090-6889:2017:Iwagaitsu S:improvement:of:arterial
1	2090-6889:2016:Tsurukawa S:herpes:zoster:meningitis
1	2090-6889:2015:Iwata Y:three:cases:of
1	2090-6889:2014:Saito E:a:case:of
1	2090-6889:2013:Naniwa T:successful:use:of
1	2090-6889:2012:Tada A:anti:interleukin:receptor
1	2090-6889:2012:Campos M:pulmonary:arterial:hypertension
1	2090-6803:2018:Rafiq N:tocilizumab:for:the
1	2090-6803:2016:Watanabe K:a:case:of
1	2090-6668:2020:Benucci M:efficacy:of:tocilizumab
1	2090-6668:2017:Tsuzaki K:rheumatoid:meningitis:occurring
1	2090-6641:2014:Matsui M:therapeutic:benefits:of
1	2090-6609:2016:Szeto M:successful:use:of
1	2090-6587:2013:Drepper M:tocilizumab:induced:acute
1	2090-6560:2016:Simons M:tafro:syndrome:associated
1	2090-6501:2019:L Pez Mu Oz B:an:unusual:amyloid
1	2090-6447:2014:Yamagata K:severe:pulmonary:suppuration
1	2090-6420:2017:Morel G:anasarca:fever:thrombocytopenia
1	2090-5467:2013:Athanasakis K:investigating:the:value
1	2090-4592:2013:Ludwig R:clinical:presentation:pathogenesis
1	2090-2999:2011:Tai Y:antibody:based:therapies
1	2090-1852:2012:Oh J:neuromyelitis:optica:an
1	2090-004X:2020:Xu J:the:therapeutic:effect
1	2090-004X:2014:Maya J:emerging:therapies:for
1	2077-0383:2020:Barbieri M:safety:profile:of
1	2076-9172:2016:Baron M:targeted:therapy:in
1	2072-1439:2019:Wojty M:clinicopathological:comparison:and
1	2057-4347:2015:Kobayashi T:interleukin:receptor:inhibitor
1	2056-6360::Meszaros E:blockade:of:recombinant
1	2056-5933:2019:Virone A:comparative:effect:of
1	2056-5933:2018:Strand V:impact:of:tocilizumab
1	2056-5933:2018:Lauper K:comparative:effectiveness:of
1	2056-5933:2017:Strand V:impact:of:tocilizumab
1	2056-5933:2017:Prieto Gonzalez S:serum:osteopontin:a
1	2056-5933:2017:Flipo R:factors:influencing:the
1	2056-5933:2016:Rubbert Roth A:malignancy:rates:in
1	2056-5933:2016:Evans J:long:term:efficacy
1	2056-5933:2016:Cabrera N:tocilizumab:in:the
1	2056-5933:2015:Izumi K:tocilizumab:is:effective
1	2056-5623:2019:De Lucena Valim J:switching:of:biological
1	2055-6837:2020:Acanfora D:neprilysin:inhibitor:angiotensin
1	2053-8855:2016:Nadesalingam K:halo:naevi:vitiligo
1	2053-3624:2018:Ueland T:serum:pcsk:is
1	2051-3380:2016:Sakashita K:an:anterior:mediastinal
1	2051-1426:2018:Horisberger A:a:severe:case
1	2050-313X:2014:Mokuda S:tocilizumab:improved:clinical
1	2050-0904:2015:Tatekawa S:thalidomide:for:tocilizumab
1	2048-8505:2015:Greenhall G:what:is:new
1	2047-9956:2019:Martinez L Pez De Castro N:content:analysis:of
1	2047-9956:2016:Beck M:biosimilar:infliximab:for
1	2045-8932::Hernandez Sanchez J:clinical:trial:protocol
1	2045-8932:2019:Holthaus N:transition:from:parental
1	2045-8932:2019:Gu X:products:of:oxidative
1	2045-0885:????:Simeone E:immunotherapy:in:metastatic
1	2042-0986:2015:Borg J:european:union:pharmacovigilance
1	2041-5990:2015:Ogata A:subcutaneous:formulation:of
1	2041-3203:2014:Pryde D:chapter:definitions:history
1	2041-3203:2014:Gopalsamy A:chapter:anti:inflammatory
1	2041-3203:2014:Carven G:chapter:biotherapeutics:for
1	2041-3203:2014:Allerton C:chapter:the:disease
1	2041-3203:2012:Ratcliffe A:chapter:the:drug
1	2041-3203:2012:Hodes G:chapter:the:neurobiology
1	2040-6223:2019:Pithadia D:tildrakizumab:in:the
1	2040-6223:2017:Roberts J:update:on:the
1	2040-6223:2013:Kaneko A:tocilizumab:in:rheumatoid
1	2040-6207:2020:Riedell P:safety:and:efficacy
1	2040-6207:2020:Jain T:management:of:toxicities
1	2040-6207:2019:Swan D:current:and:emerging
1	2040-6207:2019:Srinagesh H:biomarkers:in:acute
1	2040-6207:2016:Sarosiek S:review:of:siltuximab
1	2040-6207:2016:Papadantonakis N:recent:advances:and
1	2036-7430:2020:Nicastri E:national:institute:for
1	2013-2514:2020:L Pez V:recommendations:on:management
1	1976-9148:2019:Kim J:pbt:a:novel
1	1976-1902:2019:Iida K:kyphosis:progression:after
1	1948-5182:2015:Nard F:risk:of:hepatitis
1	1948-0210:2015:Heiblig M:adoptive:immunotherapy:for
1	1942-2962:2019:Punekar R:real:world:dose
1	1942-2962:2018:Bonafede M:treatment:persistence:and
1	1942-2962:2017:Atzinger C:biologic:disease:modifying
1	1942-0900:2020:Visentin A:targeting:inflammatory:mitochondrial
1	1942-0900:2019:Marchio P:targeting:early:atherosclerosis
1	1942-0900:2019:Butturini E:natural:sesquiterpene:lactones
1	1942-0862:2019:Krawczyk K:looking:for:therapeutic
1	1942-0862:2016:Pottier J:rethinking:the:inn
1	1942-0862:2013:Klohn P:ibc:s:rd
1	1942-0862:2012:Reichert J:marketed:therapeutic:antibodies
1	1942-0862:2012:Ducancel F:molecular:engineering:of
1	1942-0862:2010:Beck A:th:european:antibody
1	1936-9719:2008:Bingham C:emerging:therapeutics:for
1	1936-9719:2007:Strand V:interleukin:inhibition:tolerability
1	1936-9719:2007:Park J:interleukin:in:the
1	1936-9719:2007:Kavanaugh A:interleukin:inhibition:and
1	1936-9719:2007:Haines K:juvenile:idiopathic:arthritis
1	1936-9719:2007:Cronstein B:interleukin:a:key
1	1935-973X:2011:Arvikar S:inflammatory:bowel:disease
1	1935-2727:2015:Javelle E:specific:management:of
1	1933-7213:2016:Patin F:combined:metabolomics:and
1	1933-2874::Garcia G Mez C:lipoprotein:a:concentrations
1	1932-6203:2017:Balandraud N:long:term:treatment
1	1931-3128:2020:Giamarellos Bourboulis E:complex:immune:dysregulation
1	1927-1212:2019:Jumic S:hemophagocytic:lymphohistiocytosis:in
1	1881-6096:2014:Yamamura T:use:of:tocilizumab
1	1880-9693:2019:Kaneko N:the:role:of
1	1880-9693:2017:Asano Y:recent:advances:in
1	1874-3129:2018:Schmalzing M:tocilizumab:in:large
1	1871-5303:2006:Nakahara H:anti:interleukin:receptor
1	1871-4021:2020:Singh A:chloroquine:and:hydroxychloroquine
1	1869-1757:2018:Annecke T:krebspatienten:in:der
1	1868-260X:2013:Emminger W:stellenwert:der:biologikatherapie
1	1868-260X:2013:Brezinschek H:biological:therapie:impfungen
1	1868-260X:2013:Axmann R:risikomanagement:bei:rheumatoider
1	1868-260X:2012:Emminger W:therapie:der:juvenilen
1	1868-260X:2012:Dunky A:eular:in:berlin
1	1868-260X:2011:Stingl K:wirkungen:und:interaktionen
1	1868-260X:2011:Puchner R:perspektiven:der:biologika
1	1864-6158:2017:Sen M:mechanism:of:action
1	1863-2297:2013:Nguyen N:aryl:hydrocarbon:receptor
1	1863-2297:2012:Raimondo G:occult:hbv:infection
1	1863-2297:2011:Marigo I:the:immunomodulatory:properties
1	1862-8346:2016:Mcardle A:developing:clinically:relevant
1	1862-8346:2016:Lee J:remodeling:of:plasma
1	1862-040X:2020:Braun G:nebenwirkungen:neuer:onkologischer
1	1862-040X:2012:Wagner A:nierenbeteiligung:im:rahmen
1	1862-040X:2011:Schwarting A:nierenbeteiligung:beim:systemischen
1	1862-040X:2011:Forger F:autoimmune:rheumatische:erkrankungen
1	1862-040X:2008:Schwarting A:die:nierenbeteiligung:beim
1	1862-040X:2008:Elitok S:pathogenese:und:diagnostik
1	1861-9681:2013:Von Arnim U:jahrelang:persistierende:gelenkbeschwerden
1	1860-7179:2016:Steinhagen H:igniting:small:molecule
1	1860-6768:2012:Van Beers M:minimizing:immunogenicity:of
1	1857-9345:2018:Gucev F:epidemiological:analysis:and
1	1844-122X:2014:Purcarea A:cardiovascular:disease:risk
1	1828-695X:2019:Ciancio N:contribution:of:pulmonary
1	1828-0447:2020:Testa S:switch:from:oral
1	1810-6838:2019:Latimer L:ers:international:congress
1	1792-1074:2018:Xu B:prognostic:value:of
1	1792-1074:2018:Fang P:ire:xbp:signaling
1	1792-1074:2015:Kim N:anti:proliferative:action
1	1792-0981:2020:Zhou D:main:tract:stenosis
1	1792-0981:2019:Ancuceanu R:an:inventory:of
1	1792-0981:2015:Jiang P:intracisternal:administration:of
1	1791-2997:2020:Liu C:lncrna:casc:downregulation
1	1791-2997:2019:Yang J:il:increases:the
1	1791-2997:2019:Hou C:microrna:a:p
1	1771-0081:2012:Wendling D:therapeutique:des:spondylarthrites
1	1771-0081:2012:Pertuiset E:traitement:de:la
1	1771-0081:2011:Maravic M:cout:annuel:de
1	1771-0081:2011:Catros F:certaines:biotherapies:bloquent
1	1771-0081:2011:Bader Meunier B:rhumatologie:pediatrique:les
1	1759-8885:2010:Simoens S:monoclonal:antibodies:indications
1	1759-7706:2020:Zhuang J:clinical:diagnosis:and
1	1759-7706:2020:Si X:management:of:immune
1	1759-7706:2020:Ke W:the:role:of
1	1759-7706:2019:Zhou J:management:of:immune
1	1759-7706:2019:Wang H:clinical:diagnosis:and
1	1759-7706:2014:Liu Y:intrapulmonary:unicentric:castleman
1	1759-720X:2020:Koutsianas C:reactivation:of:hepatitis
1	1759-720X:2020:Glaubitz S:new:insights:into
1	1759-720X:2019:Xie W:effect:of:tofacitinib
1	1759-720X:2019:Magro R:biological:therapies:and
1	1759-720X:2019:Low C:current:advances:in
1	1759-720X:2019:Leon L:indicator:opportunistic:infections
1	1759-720X:2019:Hayashi K:thrombocytosis:as:a
1	1759-720X:2019:Del Giorno R:new:onset:cutaneous
1	1759-720X:2019:Bodkhe R:the:role:of
1	1759-720X:2018:Jones G:new:insights:and
1	1759-720X:2016:Tournadre A:managing:cardiovascular:risk
1	1759-720X:2016:Reid D:latest:therapeutic:advances
1	1759-720X:2016:Espinoza F:remission:induction:therapies
1	1759-720X:2014:Messori A:biological:drugs:for
1	1759-720X:2014:Krause M:use:of:dmards
1	1759-720X:2013:Rao V:latest:advances:in
1	1759-720X:2012:Yokota S:efficacy:safety:and
1	1759-720X:2012:Albayda J:novel:approaches:in
1	1759-720X:2010:Westhovens R:the:efficacy:and
1	1759-720X:2009:Burgos P:understanding:personalized:medicine
1	1759-5061:2020:Ronco C:kidney:involvement:in
1	1759-4790:2020:Robinson P:the:covid:global
1	1759-4790:2020:Choy E:translating:il:biology
1	1759-4790:2019:Donlin L:insights:into:rheumatic

Manipulations en shell (Unix/Dilib)

HfdCat /Users/jacquesducloy/Documents/WicriRoot/Wicri/Sante/explor/Tocilizumab.storage/TocilizumabV1/Data/Main/Merge/Idat.i.hfd| SxmlCut idx/l | grep ...

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

	Serveur d'exploration Tocilizumab - Merge (Accueil) Index « Idat.i » - tête de navigation
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Tocilizumab - Merge (Accueil)Index « Idat.i » - tête de navigation

Index : Idat.i

Les termes de plus forte occurence

Manipulations en shell (Unix/Dilib)

Serveur d'exploration Tocilizumab - Merge (Accueil)

Index « Idat.i » - tête de navigation